Patent 9,186,346 scope and claims: teriflunomide plus rosuvastatin dose-limiting methods for multiple sclerosis in the US
United States Patent 9,186,346 is a method-of-treatment patent that narrows eligibility to multiple sclerosis (MS) patients receiving co-administration of teriflunomide and rosuvastatin, with explicit dose limits designed to mitigate drug-drug interaction risk. The enforceable core is dosing: (i) teriflunomide at about 7 mg or 14 mg daily and (ii) rosuvastatin either at about 50% of the normal rosuvastatin dose or at a rosuvastatin dose that does not exceed 10 mg once daily. Dependent claims add MS subtype (relapsing forms) and timing (same-time co-administration).
What are the independent claim elements of US Patent 9,186,346 and how are they scoped?
Independent claim 1 (core dosing scheme A) and independent claim 5 (core dosing scheme B) each require all elements below to be present in the accused method:
Claim 1: MS + teriflunomide dose + “about 50%” rosuvastatin dose
- Indication: patient “having multiple sclerosis.”
- Concomitant therapy: rosuvastatin is co-administered with teriflunomide.
- Teriflunomide daily dose: administering about 7 mg or 14 mg daily.
- Rosuvastatin dose constraint: administering rosuvastatin at about 50% of the normal dose of rosuvastatin.
- Interaction-risk framing: method is for “treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction.”
Claim 5: MS + teriflunomide dose + rosuvastatin cap at 10 mg once daily
- Indication: patient “having multiple sclerosis.”
- Concomitant therapy: rosuvastatin is co-administered with teriflunomide.
- Teriflunomide daily dose: administering about 7 mg or 14 mg daily.
- Rosuvastatin maximum: administering rosuvastatin at a dose that does not exceed 10 mg once daily.
- Interaction-risk framing: “managing the risk of teriflunomide and rosuvastatin interaction.”
Scope implication: The “risk management” language does not replace the dosing limitations. It is a purpose statement tethered to the dosing constraints, so it is most likely used to interpret the claim construction around the interaction and dose-reduction rationale, while the infringement hinge remains the dosing numbers and co-administration relationship.
How is “co-administered” likely interpreted for infringement under claim 1 and claim 5?
The independent claims require rosuvastatin is co-administered with teriflunomide. Dependent claims then specify co-administered at the same time.
Dependent claims 3, 4, 7, 8: timing narrowing
- Claim 3/4: same-time co-administration (for claims 1 and 2, respectively).
- Claim 7/8: same-time co-administration (for claims 5 and 6, respectively).
Practical construction:
- For independent claims 1 and 5, infringement can occur even if rosuvastatin is not taken “at the same time,” as long as it is co-administered with teriflunomide (i.e., both are administered during overlapping treatment periods).
- For the same-time dependent claims, the accused regimen must align with simultaneous dosing.
Design-around angle: If a competitor uses rosuvastatin at a higher dose while timing administration outside “same time” windows, that may avoid dependent claims 3/4/7/8 but not the independent dosing-limits. Conversely, if they comply with the teriflunomide dose and rosuvastatin cap/dose-reduction, timing becomes less relevant to independent claim infringement.
What does “about 50% of the normal dose” mean in claim 1, and where are the numeric edges?
Claim 1 requires rosuvastatin at about 50% of the normal dose. Claim 5 uses a different numeric constraint: does not exceed 10 mg once daily.
Two separate quantitative formulations
- Relative dose constraint (claim 1): “about 50%” of the “normal dose.” This introduces ambiguity because “normal dose” depends on the prescriber’s standard regimen, patient-specific titration, and label or guideline dosing.
- Absolute dose cap (claim 5): “does not exceed 10 mg once daily.” This is more concrete and typically easier to apply.
Enforcement leverage
- Claim 5 likely provides the cleaner infringement hook in litigation due to a hard cap.
- Claim 1 can still be enforced, but disputes may arise about baseline “normal dose” and whether the administered dose falls within “about” tolerance.
Landscape impact: If generic or authorized prescribers adopt rosuvastatin dosing at or below 10 mg once daily during teriflunomide therapy, claim 5 becomes the dominant risk point. If they dose above 10 mg but attempt to argue “normal dose × 50%,” claim 1 becomes the battleground.
How do the dependent claims narrow the patent to MS subtype and dosing timing?
Relapsing forms limitation (claims 2 and 6)
- Claim 2 depends from claim 1 and limits to relapsing forms of MS.
- Claim 6 depends from claim 5 and limits to relapsing forms of MS.
Scope implication:
- Independent claims cover “multiple sclerosis” broadly, without subtype restriction.
- Dependent claims add an MS subtype. That means an accused regimen for non-relapsing forms could still infringe independently if it meets the teriflunomide and rosuvastatin dosing constraints.
Same-time co-administration limitation (claims 3, 4, 7, 8)
- Dependent claims further require co-administration at the same time.
- These claims have narrower reach but can strengthen a patentee’s infringement theory if the accused regimen involves synchronized dosing.
What is the likely claim interpretation of the “about 7 or 14 mg teriflunomide daily” limitation?
Both independent claims require:
- Teriflunomide dose: about 7 mg or 14 mg daily.
Scope implication:
- This maps to conventional teriflunomide daily dosing strengths used in MS treatment (a “low dose” and “standard dose” framing).
- The “about” language likely permits small deviations from exact 7 or 14 mg, subject to claim construction standards.
Design-around angle: A regimen using materially different daily teriflunomide doses (outside “about” 7 or 14 mg) would avoid the independent claims, assuming the dosing is not within construed tolerance.
How does the patent treat rosuvastatin dose reduction, and what dosing scenarios are most likely covered?
Because the claims are tied to either “about 50% of normal dose” (claim 1) or “≤10 mg once daily” (claim 5), coverage likely includes:
Scenario likely covered by claim 5
- A patient is prescribed teriflunomide (7 mg or 14 mg daily) for MS.
- Rosuvastatin is continued during the same treatment period but limited to ≤10 mg once daily to manage interaction risk.
Scenario likely covered by claim 1
- A patient is on teriflunomide (7 mg or 14 mg).
- Rosuvastatin is given at a dose that is roughly half of a “normal” regimen as defined in the patient’s prescriber context.
Scenario likely NOT covered
- Teriflunomide is at ~7 or ~14 mg, but rosuvastatin is dosed above 10 mg once daily during co-administration and does not clearly meet “about 50%” of the patient’s “normal dose.”
Litigation leverage: The absolute cap in claim 5 gives a sharper line for proving infringement if the accused dosing history is documented.
What patent landscape surrounds US 9,186,346 for teriflunomide and interaction management?
A full landscape typically requires the patent’s bibliographic data (assignee, filing/grant dates) and the complete family, plus the Orange Book listing set for the relevant teriflunomide product(s). Without that, only the claim-level landscape can be addressed: this patent is an interaction-management dosing patent rather than a formulation, composition, or novel active ingredient patent.
Likely landscape buckets
- Method-of-use dosing patents for specific co-administered drug pairs.
- General teriflunomide MS treatment patents (covering use of teriflunomide for MS, not the rosuvastatin dose-limiting interaction management).
- Rosuvastatin label/labeling-related patents (less likely to be interaction-specific).
- Other interaction management patents for different statins or CYP-related combinations.
Business implication: This patent’s value sits in prescribing and clinical protocol space: it is asserted to control how rosuvastatin is dosed during teriflunomide therapy, not to block teriflunomide manufacture or rosuvastatin manufacture.
When does US 9,186,346 lose exclusivity, and how does timing affect generic and clinical adoption risk?
Exclusivity timing depends on the patent’s filing date, priority date, and any adjustment. Without the patent’s bibliographic and term data, exact expiration cannot be stated from the claim text alone.
However, timing risk pattern is consistent for method-of-use patents:
- As expiration approaches, the risk decreases for newly adopted clinical protocols.
- Existing payer/PMI restrictions often persist until legal outcomes or guideline updates change standard practice.
How strong is the claim enforceability based on specificity of dosing numbers?
Strength indicators from the claim set:
- The claims include numeric teriflunomide doses (about 7 mg or 14 mg daily).
- The claims include numeric rosuvastatin constraints (about 50% of normal dose or ≤10 mg once daily).
- Dependent claims add MS subtype and same-time co-administration.
Enforceability implication:
- Specific numbers usually improve infringement proof when patient dosing records are available (electronic health record and pharmacy claims).
- The “about” terms create interpretive flexibility, but they still anchor the claim to quantifiable regimens.
Vulnerability indicator:
- The “about 50% of normal dose” phrase can be harder to prove than an absolute cap because “normal dose” is context-dependent. Claim 5’s cap likely mitigates this vulnerability.
What generic entry or biosimilar risks exist for method-of-treatment claims like this?
Method-of-use patents are not “entered” in the typical Orange Book sense the way drug products are. But they still affect market behavior:
- Generic rosuvastatin and generic teriflunomide do not automatically avoid method claims.
- If a generic or brand prescriber follows the dosing regimen that fits the claims, there is still potential infringement exposure for the performing/using entity (often implicated through direct or induced infringement theories, depending on jurisdiction and proof strategy).
Commercial risk shift:
- The practical risk is on clinical protocol and prescriber/payer enforcement, not on manufacturing bottlenecks.
How would litigation typically frame infringement for US 9,186,346?
For claims 1 and 5, plaintiffs typically build a record around:
- Prescription evidence: teriflunomide dose (7 or 14 mg “about”).
- Concomitant rosuvastatin dosing: showing either (a) ≤10 mg once daily during co-administration (best for claim 5) or (b) near “50% of normal dose” (best for claim 1).
- Co-administration timeline: proving overlapping administration (independent) and same-time dosing (dependent).
- Diagnosis: MS diagnosis, and if needed, relapsing-form status (dependent claims 2 and 6).
Key evidence types: EHR medication administration timestamps, pharmacy dispensing records, dose titration histories, and MS diagnosis codes.
Key design-around pathways implied by the claim text
Based on the claim limitations, plausible avoidance strategies (from an accused actor’s perspective) are:
- Avoid the rosuvastatin constraint: dose rosuvastatin above 10 mg once daily during teriflunomide co-administration, or do not maintain “about 50%” of normal dosing.
- Avoid the teriflunomide dose anchor: use a teriflunomide daily dose outside “about 7 mg or 14 mg.”
- Avoid same-time co-administration: structure dosing schedules to avoid “same time” overlap (this only helps for dependent claims, not independent claims).
- Treat a non-MP subtype: relapsing-form limitations only matter for dependent claims 2 and 6.
Key Takeaways
- US 9,186,346 is a method-of-treatment patent focused on teriflunomide plus rosuvastatin co-administration in MS.
- The enforceable core is dosing control: teriflunomide about 7 mg or 14 mg daily plus rosuvastatin at either about 50% of normal dose (claim 1) or ≤10 mg once daily (claim 5).
- Dependent claims narrow to relapsing MS and to same-time co-administration, strengthening infringement theories when prescribing records match.
- The strongest infringement hook is likely claim 5’s absolute rosuvastatin cap due to clearer proof.
- The competitive impact is mainly on prescribing protocols during co-administration, not on generic product launch mechanics.
FAQs
1) Does US 9,186,346 require rosuvastatin to be dosed at exactly 50%?
No. The claim uses “about 50%,” so infringement turns on whether the administered dose falls within the claim construction of “about,” which is anchored to the “normal dose” baseline.
2) Can infringement occur without “same time” dosing?
Yes. Claims 1 and 5 require co-administration, not simultaneous dosing. “Same time” is only specified in dependent claims.
3) If a patient is not in a relapsing MS subtype, can they still infringe?
Yes. Relapsing-form limitations are only in dependent claims (2 and 6). Independent claims cover “multiple sclerosis” more broadly.
4) Is the patent blocked by generic rosuvastatin or teriflunomide approvals?
Generic approvals do not eliminate method-of-use infringement risk if the clinician/patient regimen meets the claimed dosing constraints during co-administration.
5) Which claim is easier to enforce: claim 1 or claim 5?
Claim 5 is typically easier because it uses an absolute numeric cap on rosuvastatin (≤10 mg once daily) rather than a relative “about 50% of normal dose” construct.
References
- US Patent 9,186,346 (claim text provided in prompt).
